ArticleCureus2026
Postoperative Day 1 Mean Arterial Pressure and 30-Day Mortality or Day 7 Renal Replacement Therapy After Ventricular Assist Device Implantation.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background The association between mean arterial pressure (MAP) early after ventricular assist device (VAD) implantation and short-term outcomes remains incompletely characterized. Our primary objective was to examine the association of postoperative day (POD) 1 MAP with death within 30 days or renal replacement therapy (RRT) on POD 7, accounting for initial support. Secondary exploratory objectives concerned other hemodynamic markers and subsequent renal and hepatic laboratory outcomes. Methods This single-center exploratory retrospective cohort included patients aged 18 years or older at an eligible index procedure between July 1, 2019, and March 31, 2025. Groups A-D represented initial VAD support strategies at the index procedure: (A) HeartMate 3 (Abbott Medical, Pleasanton, CA; HM3) alone; (B) HM3 with right ventricular assist device (RVAD) support; (C) extracorporeal left ventricular assist device (LVAD) alone; and (D) extracorporeal LVAD with RVAD support. Later support changes did not alter group assignment. The exposure was the median invasive MAP on POD 1. The composite outcome was death within 30 days or RRT on POD 7. Firth logistic regression included initial strategy and MAP centered within strategy. Seven hemodynamic markers were examined with Holm adjustment. Results The cohort comprised 156 patients (A, 92; B, five; C, 31; D, 28). The outcome was ascertainable in 146 patients, including 22 (15.1%) with events. Each 5-mmHg higher MAP was associated with lower odds of the outcome (odds ratio (OR), 0.217; 95% confidence interval (CI), 0.082-0.501; P < 0.001; Holm-adjusted P < 0.001). Mean perfusion pressure (MPP) was also associated with the outcome (OR per 5 mmHg, 0.412; 95% CI, 0.213-0.729). In a joint model, MAP remained associated (OR, 0.235; 95% CI, 0.085-0.553), whereas right atrial pressure did not. Sensitivity analyses showed the same direction of association. MAP was not clearly associated with subsequent creatinine or bilirubin summaries. Conclusions Lower invasive MAP on POD 1 was associated with early death or RRT on POD 7 after accounting for initial VAD support. These exploratory findings support further evaluation of MAP as an early risk marker; the effects and targets of interventions to increase MAP require further study.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.